A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1748-717X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy ; volume:8 ; number:1 ; day:8 ; month:7 ; year:2013 ; pages:1-8 ; date:12.2013
Radiation oncology ; 8, Heft 1 (8.7.2013), 1-8, 12.2013

Urheber
Jackson, William C.
Beteiligte Personen und Organisationen
Johnson, Skyler B.
Li, Darren
Foster, Corey
Foster, Benjamin
Song, Yeohan
Schipper, Matthew
Shilkrut, Mark
Sandler, Howard M.
Morgan, Todd M.
Palapattu, Ganesh S.
Hamstra, Daniel A.
Feng, Felix Y.
SpringerLink (Online service)

DOI
10.1186/1748-717X-8-170
URN
urn:nbn:de:1111-201604097216
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:54 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Jackson, William C.
  • Johnson, Skyler B.
  • Li, Darren
  • Foster, Corey
  • Foster, Benjamin
  • Song, Yeohan
  • Schipper, Matthew
  • Shilkrut, Mark
  • Sandler, Howard M.
  • Morgan, Todd M.
  • Palapattu, Ganesh S.
  • Hamstra, Daniel A.
  • Feng, Felix Y.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Biomarkers for prostate cancer: prostate-specific antigen and beyond

Biomarkers for prostate cancer: prostate-specific antigen and beyond

The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity

The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy

Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy

Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy

Prostate-specific antigen-based screening: controversy and guidelines

Prostate-specific antigen-based screening: controversy and guidelines

Prostate-specific antigen testing accuracy in community practice

Prostate-specific antigen testing accuracy in community practice

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma

Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients

Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients

Verbundene Objekte